Kintor Pharmaceutical Ltd (9939) AI Stock Analysis

• Market Cap: HK$651.62M
• Dividend Yield: N/A
• Average Volume (3M): 3.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: N/A
• EPS Growth: 85.23%
• Country: HK
• Employees: 168
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 447,499,600
• 10 Day Avg. Volume: 6,995,278
• 30 Day Avg. Volume: 3,594,299
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Kintor Pharmaceutical Ltd's stock faces significant financial challenges, with persistent unprofitability and cash flow issues being the most significant concerns. Technical indicators show mixed signals, and the valuation metrics are unfavorable due to negative earnings. These factors collectively contribute to a low stock score, highlighting the need for strategic improvements.

Kintor Pharmaceutical Ltd Business Overview & Revenue Model

Company Description

Kintor Pharmaceutical Ltd (9939) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for cancer and androgen receptor-related diseases. The company operates primarily in the biotechnology and pharmaceutical sectors, with a portfolio that includes drug candidates for the treatment of prostate cancer, breast cancer, and other critical conditions.

How the Company Makes Money

Kintor Pharmaceutical Ltd generates revenue through the development and commercialization of its drug candidates. The company invests in research and development to bring its innovative therapies to market, aiming to secure approvals from regulatory bodies. Once approved, Kintor sells these therapies to healthcare providers and distributors. In addition to direct sales, the company may engage in strategic partnerships and licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on sales. These collaborative efforts can significantly contribute to Kintor's revenue, allowing the company to leverage the expertise and distribution networks of its partners.

Kintor Pharmaceutical Ltd Financial Statement Overview

Summary

Kintor Pharmaceutical Ltd faces significant financial challenges with negative profitability and cash flow metrics. Despite increased revenue, operational inefficiencies and high R&D costs weigh heavily on margins. The balance sheet shows moderate financial stability, yet the high liabilities and reliance on debt financing are concerning.

Income Statement

Kintor Pharmaceutical Ltd has shown a challenging financial performance in recent years. The company recorded negative gross profit and net income for the latest year, indicating difficulty in covering its cost of goods sold and operational expenses. Despite a significant increase in total revenue in 2024, the company remains unprofitable with negative EBIT and EBITDA margins, highlighting ongoing operational challenges.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a debt-to-equity ratio of 0.45, indicating a relatively controlled level of leverage. However, the company has a significant amount of liabilities compared to its assets, and the equity ratio is below optimal levels, pointing to a reliance on debt financing. The negative net income has also adversely affected the return on equity.

Cash Flow

Kintor Pharmaceutical Ltd's cash flow statements reflect significant challenges in generating cash from operations, as indicated by consistently negative operating and free cash flows. The operating cash flow to net income ratio suggests inefficiencies in converting income into cash. Despite some positive investing cash flow, the company's overall cash position remains under pressure.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.00M	0.00	0.00	34.23K	0.00
Gross Profit	-4.73M	-42.23M	0.00	34.23K	0.00
EBITDA	-136.33M	-1.06B	-956.45M	-827.97M	-396.33M
Net Income	-155.29M	-1.06B	-954.37M	-842.10K	-508.30M
Balance Sheet
Total Assets	515.13M	869.23M	2.06M	2.07M	1.85M
Cash, Cash Equivalents and Short-Term Investments	148.69M	455.50M	876.96K	1.06M	1.39M
Total Debt	133.01M	253.92M	286.39M	159.73M	221.70M
Total Liabilities	221.05M	411.12M	559.95K	412.83K	343.54K
Stockholders Equity	294.08M	458.11M	1.50M	1.66M	1.51M
Cash Flow
Free Cash Flow	-199.08M	-390.30M	-988.73K	-1.13M	-449.92K
Operating Cash Flow	-199.08M	-387.58M	-961.26K	-1.05M	-380.88K
Investing Cash Flow	20.03M	3.27M	67.19K	92.00K	-439.73K
Financing Cash Flow	-119.67M	-33.46M	815.75K	857.42K	1.78M

Kintor Pharmaceutical Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Positive. The current price of 1.48 is below the 20-day moving average (MA) of 1.53, above the 50-day MA of 1.35, and above the 200-day MA of 1.14, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 54.88 is Neutral, neither overbought nor oversold. The STOCH value of 14.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9939.

Kintor Pharmaceutical Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2318	79 Outperform	$997.37B	6.81		7.42%	11.71%	37.04%
1093	76 Outperform	$87.63B	19.06	13.20%	2.59%	-9.60%	-27.18%
2269	74 Outperform	$99.68B	28.65	8.17%	―	7.52%	-1.92%
1177	69 Neutral	HK$92.28B	48.63	6.14%	12.17%	7.63%	-24.23%
Sector *	60 Neutral	HK$15.20B	5.43	-7.43%	6.05%	11.72%	-20.69%
1873	58 Neutral	HK$3.28B	18.25	4.47%	―	-9.75%	―
9939	36 Underperform	HK$651.62M	―	-41.20%	―	―	85.23%

Kintor Pharmaceutical Ltd Corporate Events

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study

Kintor Pharmaceutical Limited announced the successful completion of a clinical observational study evaluating the efficacy and safety of KX-826 in combination with minoxidil for treating androgenetic alopecia (AGA) in male adults in China. The study demonstrated superior efficacy of the combination treatment over minoxidil monotherapy, with significant improvements in hair count and growth assessments. The results support the optimization of a future phase III clinical trial, potentially enhancing Kintor’s position in the hair loss treatment market.

Kintor Pharmaceutical Chairman Increases Shareholding, Signals Confidence in Growth

Kintor Pharmaceutical Limited announced an increase in shareholding by its Chairman, Dr. Youzhi Tong, who purchased 200,000 shares and exercised rights under 1,250,000 restricted share units, bringing his total interest to approximately 10.99% of the company’s issued share capital. This move reflects Dr. Tong’s confidence in the company’s growth potential and long-term investment value, as Kintor continues to focus on expanding its dermatology product line and exploring new markets for its cosmetic ingredients.

Kintor Pharmaceutical Reports Improved Financial Results for 2024

Kintor Pharmaceutical Ltd reported a significant improvement in its financial performance for the year ended December 31, 2024. The company’s revenue increased to RMB5.0 million, driven by global sales of its new cosmetics brand, KOSHINÉ. The net loss decreased by 85.4% due to reduced R&D costs, which fell by 91.7% as the company shifted its focus to more cost-effective dermatology pipelines. Administrative expenses also decreased, while marketing costs rose significantly to promote the cosmetics business. With cash reserves and unutilized bank credit, Kintor is poised to continue supporting its clinical trials and R&D efforts.

Kintor Pharmaceutical’s KX-826 Achieves Key Milestone in AGA Treatment

Kintor Pharmaceutical Limited announced that its long-term safety phase III clinical trial for KX-826, a potential first-in-class treatment for androgenetic alopecia (AGA), has successfully reached its primary endpoint. The trial, conducted across 16 clinical research centers in China, demonstrated statistically significant and clinically meaningful outcomes, indicating excellent safety and efficacy of the KX-826 tincture. This development could enhance Kintor’s positioning in the pharmaceutical industry, particularly in the AGA treatment market, and may have positive implications for stakeholders.

Kintor Pharmaceutical Expands Global Reach with ToMax Partnership

Kintor Pharmaceutical Limited has entered into a brand and sales operation cooperation agreement with Hangzhou ToMax Co., Ltd. to enhance the overseas market presence of its cosmetic products. This strategic partnership aims to leverage Kintor’s expertise in research, development, and manufacturing with ToMax’s marketing and promotional capabilities, thereby expanding the reach and sales of Kintor’s cosmetics globally. The collaboration is expected to result in mutual benefits and a win-win outcome for both parties, strengthening Kintor’s position in the cosmetics industry.

Kintor Pharmaceutical Schedules Board Meeting to Approve Annual Results

Kintor Pharmaceutical Ltd has announced a board meeting scheduled for March 26, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. This meeting is pivotal for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming year.